Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial

Imagem de Miniatura
Arquivos
art_ARANTES_Influence_of_Direct_Thrombin_Inhibitor_and_Low_Molecular_2020.PDF (609.2 KB)
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2020
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Autores
NOMELINI, Quintiliano S. S.
Citação
ADVANCES IN THERAPY, v.37, n.1, p.420-430, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction The interaction between anticoagulants and platelet function is complex. Previous publications showed mixed results regarding the role of heparins in platelet aggregation. On the other hand, the direct thrombin inhibitor (DTI) dabigatran might enhance the risk of myocardial infarction in patients with atrial fibrillation, which could be related to increased platelet aggregability. Methods This was a prospective, interventional study of patients with chronic coronary artery disease (CAD) taking low-dose aspirin. The objective of the current study was to compare the effects of dabigatran versus enoxaparin on platelet aggregability. Subjects initially were on orally administered dabigatran for 5 days followed by subcutaneously administered enoxaparin after a 30-day washout period. Platelet function was assessed at baseline and after each intervention by multiple electrode aggregometry (MEA-ASPI) (primary endpoint), serum thromboxane B2 (TXB2), VerifyNow Aspirin (TM), and coagulation tests (secondary endpoints). Results Compared to baseline MEA-ASPI values, dabigatran increased platelet aggregation while enoxaparin decreased platelet aggregation (+ 5 U +/- 24.1 vs - 6 U +/- 22.2, respectively, p = 0.012). The TXB2 assay showed the same pattern (+ 2 pg/ml for dabigatran vs - 13 pg/ml for enoxaparin, p = 0.011). None of the additional tests showed significant differences between the groups. Individually, compared to baseline TXB2 results, enoxaparin significantly decreased platelet activation [33 (16.5-95) pg/mL vs 20 (10-52) pg/mL, respectively, p = 0.026], but no significant differences were observed with dabigatran. Conclusions DTI and anti-Xa drugs exert opposite effects on platelet function. A significant decrease in platelet activation through COX1 (also known as prostaglandin G/H synthase 1) was observed with enoxaparin, but no significant differences in platelet function were observed with dabigatran.
Palavras-chave
Anti-Xa, Aspirin, Coronary artery disease, Direct thrombin inhibitor, Platelet aggregability
URI
https://observatorio.fm.usp.br/handle/OPI/35670
Referências
  1. Achilles A, 2017, J THROMB HAEMOST, V15, P473, DOI 10.1111/jth.13595
  2. Aggarwal A, 2004, NEPHROL DIAL TRANSPL, V19, P1559, DOI 10.1093/ndt/gfh209
  3. Aggarwal A, 2002, J THROMB THROMBOLYS, V13, P161, DOI 10.1023/A:1020478923794
  4. Antman EM, 2006, NEW ENGL J MED, V354, P1477, DOI 10.1056/NEJMoa060898
  5. Cannon CP, 2017, NEW ENGL J MED, V377, P1513, DOI 10.1056/NEJMoa1708454
  6. Connolly SJ, 2010, NEW ENGL J MED, V363, P1875, DOI 10.1056/NEJMc1007378
  7. Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
  8. Dans AL, 2013, CIRCULATION, V127, P634, DOI 10.1161/CIRCULATIONAHA.112.115386
  9. Douxfils J, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000515
  10. Eikelboom JW, 2013, NEW ENGL J MED, V369, P1206, DOI 10.1056/NEJMoa1300615
  11. Ezekowitz MD, 2007, AM J CARDIOL, V100, P1419, DOI 10.1016/j.amjcard.2007.06.034
  12. Ferguson JJ, 2004, JAMA-J AM MED ASSOC, V292, P45
  13. Fiessinger JN, 2005, JAMA-J AM MED ASSOC, V293, P681, DOI 10.1001/jama.293.6.681
  14. Franchi F, 2016, THROMB HAEMOSTASIS, V115, P622, DOI 10.1160/TH15-06-0467
  15. Gargiulo G, 2018, J AM COLL CARDIOL, V71, P1231, DOI 10.1016/j.jacc.2018.01.033
  16. Graham DJ, 2015, CIRCULATION, V131, P157, DOI 10.1161/CIRCULATIONAHA.114.012061
  17. Hohnloser SH, 2015, CHEST, V147, pE70, DOI 10.1378/chest.14-2534
  18. Hohnloser SH, 2012, CIRCULATION, V125, P669, DOI 10.1161/CIRCULATIONAHA.111.055970
  19. Laine M, 2016, INT J CARDIOL, V220, P496, DOI 10.1016/j.ijcard.2016.06.247
  20. Larsen TB, 2013, J AM COLL CARDIOL, V61, P2264, DOI 10.1016/j.jacc.2013.03.020
  21. Montalescot G, 2003, AM J CARDIOL, V91, P925, DOI 10.1016/S0002-9149(03)00105-X
  22. Oldgren J, 2011, EUR HEART J, V32, P2781, DOI 10.1093/eurheartj/ehr113
  23. Olivier CB, 2016, J THROMB THROMBOLYS, V42, P161, DOI 10.1007/s11239-016-1350-7
  24. Pollack CV, 2017, NEW ENGL J MED, V377, P431, DOI 10.1056/NEJMoa1707278
  25. Solbeck S, 2014, INT J CARDIOL, V176, P794, DOI 10.1016/j.ijcard.2014.07.084
  26. Stone GW, 2008, NEW ENGL J MED, V358, P2218, DOI 10.1056/NEJMoa0708191
  27. Taune V, 2017, THROMB RES, V153, P76, DOI 10.1016/j.thromres.2017.03.018
  28. Valgimigli M, 2015, NEW ENGL J MED, V373, P997, DOI 10.1056/NEJMoa1507854
  29. Wurtz M, 2014, PLATELETS, V25, P628, DOI 10.3109/09537104.2013.849804
  30. Xiao ZH, 1998, CIRCULATION, V97, P251, DOI 10.1161/01.CIR.97.3.251

Coleções
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - LIM/11
Artigos e Materiais de Revistas Científicas - ODS/03